Tuesday, June 16, 2026
Germany backs away from variable drug discount plan
Germany is set to abandon a planned variable discount system for branded medicines, Reuters reported. The move comes after strong objections from pharmaceutical companies.
The proposal formed part of a broader healthcare reform package intended to generate 16.3 billion euros in savings in 2027. Drug spending measures were expected to contribute 1.9 billion euros in savings next year.
Fixed approach to replace variable discounts
Under the initial plan, drugmakers would have faced higher mandatory markdowns to German health insurers based on list prices. The measure was one element of a wider effort to curb pharmaceutical expenditure.
Germany will instead pursue a fixed discount approach, Reuters reported, citing an unnamed government source. Details of the revised model have not yet been disclosed.
Companies warned of investment cuts
The plan, first presented in April, triggered rapid pushback from industry executives. Eli Lilly and Boehringer Ingelheim said they would reduce planned spending in Germany by at least 1 billion dollars each. Pfizer CEO Albert Bourla also indicated that the company was weighing a comparable response.
Novartis CEO Vas Narasimhan criticized the reform during the company’s first-quarter earnings discussion with reporters. He argued that such policies send an unhelpful signal to an innovation-driven sector at a time when the United States and China are investing actively in biotech competitiveness.
Reform debate continues
German Health Minister Nina Warken, who proposed the legislation, had defended the initiative despite the criticism. In comments to the Funke newspaper group, she said every sector needed to contribute to the reform.
The shift away from a variable discount structure does not end the policy debate over pharmaceutical savings. For manufacturers, the central question is now how the fixed model will be designed and what it could mean for pricing, reimbursement and future investment in Germany.
